Francesco Gentile

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1174512/publications.pdf

Version: 2024-02-01

25 papers 485

759233 12 h-index 752698 20 g-index

26 all docs $\begin{array}{c} 26 \\ \text{docs citations} \end{array}$

times ranked

26

394 citing authors

#	Article	IF	CITATIONS
1	Epidemiological and clinical boundaries of heart failure with preserved ejection fraction. European Journal of Preventive Cardiology, 2022, 29, 1233-1243.	1.8	16
2	Current and emerging drug targets in heart failure treatment. Heart Failure Reviews, 2022, 27, 1119-1136.	3.9	22
3	Central Apneas Are More Detrimental in Female Than in Male Patients With Heart Failure. Journal of the American Heart Association, 2022, 11 , e024103.	3.7	7
4	Left atrial thrombus and smoke resolution in patients with atrial fibrillation under chronic oral anticoagulation. Journal of Interventional Cardiac Electrophysiology, 2022, , $1.$	1.3	4
5	Chemoreflex and Baroreflex Sensitivity Hold a Strong Prognostic Value in Chronic HeartÂFailure. JACC: Heart Failure, 2022, 10, 662-676.	4.1	17
6	Circulating levels and prognostic cutâ€offs of sST2, hsâ€cTnT, and NTâ€proBNP in women vs. men with chronic heart failure. ESC Heart Failure, 2022, 9, 2084-2095.	3.1	15
7	Central apnoeas and ticagrelor-related dyspnoea in patients with acute coronary syndrome. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 180-188.	3.0	14
8	Cardiogenic shock and acute kidney injury: the rule rather than the exception. Heart Failure Reviews, 2021, 26, 487-496.	3.9	21
9	Use of hypocapnia for improved risk stratification in pulmonary arterial hypertension: should we return to respiratory pathophysiology?. International Journal of Cardiology, 2021, 329, 208.	1.7	О
10	Sacubitril–valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction. International Journal of Cardiology, 2021, 330, 112-119.	1.7	14
11	The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease. European Journal of Heart Failure, 2021, 23, 1458-1467.	7.1	29
12	Novel Drug Targets for Central Apneas in Heart Failure: On the Road. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 490-491.	5 . 6	O
13	Coronary Artery Anomalies. Circulation, 2021, 144, 983-996.	1.6	77
14	NT-proBNP for Risk Prediction in HeartÂFailure. JACC: Heart Failure, 2021, 9, 653-663.	4.1	20
15	Hide and seek. Ticagrelor and central apneas after acute coronary syndrome. Sleep Medicine, 2021, 86, 125.	1.6	O
16	Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets. Heart Failure Reviews, 2021, 26, 881-890.	3.9	43
17	$41\hat{a} \in f$ Circulating levels and prognostic cut-offs of sST2, high-sensitivity troponin T, and NT-proBNP in women vs. men with chronic heart failure. European Heart Journal Supplements, 2021, 23, .	0.1	1
18	Reply. Journal of the American College of Cardiology, 2020, 76, 2040-2041.	2.8	0

#	Article	IF	CITATION
19	Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction. European Journal of Preventive Cardiology, 2020, , 204748732092761.	1.8	21
20	Upright Cheyne-Stokes Respiration in Patients With HeartÂFailure. Journal of the American College of Cardiology, 2020, 75, 2934-2946.	2.8	31
21	COVID-19 and risk of pulmonary fibrosis: the importance of planning ahead. European Journal of Preventive Cardiology, 2020, 27, 1442-1446.	1.8	69
22	Gender-Related Differences in Clinical Presentation and Angiographic Findings in Patients with Ischemia and No Obstructive Coronary Artery Disease (INOCA): A Single-Center Observational Registry. International Journal of Angiology, 2020, 29, 250-255.	0.6	6
23	Contribution of the Lung to the Genesis of Cheyneâ€Stokes Respiration in Heart Failure: Plant Gain Beyond Chemoreflex Gain and Circulation Time. Journal of the American Heart Association, 2019, 8, e012419.	3.7	28
24	Central and Obstructive Apneas in Heart Failure With Reduced, Mid-Range and Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2019, 6, 125.	2.4	25
25	Bioelectronic medicine and it's applications in cardiology. European Heart Journal, 0, , .	2.2	4